US Patent

US9511046 — Methods of treating pancreatic cancer

Method of Use · Assigned to Abraxis Bioscience LLC · Expires 2034-01-12 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

Methods are provided for treating metastatic pancreatic cancer by administering a composition of nanoparticles containing paclitaxel and a carrier protein with gemcitabine.

USPTO Abstract

Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Drugs covered by this patent

chembl-chembl428647 (PACLITAXEL)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1434`	—	chembl-chembl428647

Patent Metadata

Patent number: US9511046
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-12
Drug substance claim: No
Drug product claim: No
Assignee: Abraxis Bioscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.